Advantage Alpha Capital Partners LP Trims Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Advantage Alpha Capital Partners LP trimmed its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 43.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 87,391 shares of the biotechnology company’s stock after selling 66,160 shares during the period. Advantage Alpha Capital Partners LP’s holdings in ADMA Biologics were worth $1,747,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co grew its holdings in shares of ADMA Biologics by 114.3% during the first quarter. CANADA LIFE ASSURANCE Co now owns 54,049 shares of the biotechnology company’s stock worth $357,000 after purchasing an additional 28,832 shares during the last quarter. Shell Asset Management Co. acquired a new position in ADMA Biologics during the first quarter worth approximately $155,000. EntryPoint Capital LLC purchased a new stake in ADMA Biologics in the first quarter valued at approximately $31,000. 1832 Asset Management L.P. acquired a new stake in shares of ADMA Biologics in the first quarter valued at approximately $899,000. Finally, Lazard Asset Management LLC grew its position in shares of ADMA Biologics by 5.5% during the first quarter. Lazard Asset Management LLC now owns 110,809 shares of the biotechnology company’s stock worth $730,000 after acquiring an additional 5,731 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This trade represents a 5.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jerrold B. Grossman sold 136,861 shares of the company’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the transaction, the director now directly owns 467,305 shares in the company, valued at approximately $8,070,357.35. This trade represents a 22.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 185,011 shares of company stock valued at $3,255,204. 3.70% of the stock is owned by corporate insiders.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $21.47 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a market cap of $5.08 billion, a price-to-earnings ratio of 76.68 and a beta of 0.64. The firm’s fifty day moving average price is $18.92 and its 200 day moving average price is $15.05. ADMA Biologics, Inc. has a 1-year low of $3.60 and a 1-year high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter in the previous year, the firm earned $0.01 earnings per share. On average, sell-side analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on ADMA shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. Raymond James upped their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. Finally, HC Wainwright raised their price target on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.